Taxanes in combination with biologic agents for ovarian and breast cancers

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Anti-Cancer Drugs

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0000000000000056PMID 24300916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy

  2015cited by this paper
• Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

  2013cited by this paper
• Pertuzumab in breast cancer: a systematic review.

  2013cited by this paper
• Targeted anti-vascular therapies for ovarian cancer: current evidence

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2013cited by this paper
• Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

  2013cited by this paper
• Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

  2013cited by this paper
• Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group

  2013cited by this paper
• The pharmacological bases of the antiangiogenic activity of paclitaxel

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

  2013cited by this paper
• Major clinical research advances in gynecologic cancer in 2012

  2013cited by this paper
• Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.

  2013cited by this paper
• Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

  2013cited by this paper
• Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  2013cited by this paper
• Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

  2013cited by this paper
• Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

  2013cited by this paper
• The VEGF signaling pathway in cancer: the road ahead

  2013cited by this paper
• Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

  2012cited by this paper
• Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

  2012cited by this paper
• A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

  2012cited by this paper
• Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.

  2012cited by this paper
• Current approaches to the management of Her2-negative metastatic breast cancer

  2012cited by this paper
• Update on taxane development: new analogs and new formulations

  2012cited by this paper
• An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

  2012cited by this paper
• Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

  2012cited by this paper
• Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• The role of bevacizumab in advanced epithelial ovarian cancer.

  2012cited by this paper
• Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer

  2012cited by this paper
• Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

  2012cited by this paper
• Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

  2012cited by this paper
• A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

  2012cited by this paper
• Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

  2012cited by this paper
• Three ongoing intraperitoneal chemotherapy trials in ovarian cancer

  2012cited by this paper
• Avastin loses breast cancer indication

  2012cited by this paper
• Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

  2012cited by this paper
• Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

  2012cited by this paper
• A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

  2012cited by this paper
• Neoadjuvant treatments for triple-negative breast cancer (TNBC).

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

  2012cited by this paper
• Targeting angiogenesis in metastatic breast cancer.

  2012cited by this paper
• Ovarian Cancer: Opportunity for Targeted Therapy

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.

  2011cited by this paper
• Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

  2011cited by this paper
• Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).

  2011cited by this paper
• Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

  2011cited by this paper
• VEGF inhibitors and advanced ovarian cancer.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

  2011cited by this paper
• Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

  2011cited by this paper
• Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer

  2011cited by this paper
• Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.

  2011cited by this paper
• Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

  2011cited by this paper
• Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.

  2011cited by this paper
• SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

  2011cited by this paper
• PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

  2011cited by this paper
• Taxanes: promising anti-cancer drugs.

  2011cited by this paper
• [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].

  2011cited by this paper
• RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

  2011cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

  2010cited by this paper
• Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

  2010cited by this paper
• Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

  2010cited by this paper
• Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

  2010cited by this paper
• Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  2010cited by this paper
• Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

  2010cited by this paper
• Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198

  2010cited by this paper
• A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

  2010cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.

  2010cited by this paper
• Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

  2010cited by this paper
• A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells

  2010cited by this paper
• A Current Review of Targeted Therapeutics for Ovarian Cancer

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs

  2010cited by this paper
• Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

  2010cited by this paper
• Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.

  2010cited by this paper
• Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

  2010cited by this paper

• Synergistic ferroptosis in triple-negative breast cancer cells: Paclitaxel in combination with Erastin induced oxidative stress and Ferroportin-1 modulation in MDA-MB-231 cells

  2024cites this paper
• PLAG1 silencing promotes cell chemosensitivity in ovarian cancer via the IGF2 signaling pathway

  2020cites this paper
• Breast Cancer Agents: Treatment & Prevention

  2014cites this paper
• A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer.

  2014cites this paper
• Breast Cancer Agents: Treatment

  2014cites this paper
• Class III beta-tubulin, drug resistance and therapeutic approaches in cancers

  2014cites this paper